Teclistamab (Tecvayli) has been recommended for use by the NHS in England and Wales as a fourth-line option for treating relapsed and refractory multiple myeloma in adults. In final draft guidance, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback